Biogen, Inc. (BIIB)
250.48
-2.92
(-1.15%)
USD |
NASDAQ |
Nov 12, 16:00
250.69
+0.21
(+0.08%)
After-Hours: 20:00
Biogen Free Cash Flow (Quarterly) : 375.40M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 375.40M |
| June 30, 2026 | 308.00M |
| March 31, 2026 | 559.30M |
| December 31, 2025 | 401.70M |
| September 30, 2025 | 1.221B |
| June 30, 2025 | 134.30M |
| March 31, 2025 | 212.20M |
| December 31, 2024 | 694.60M |
| September 30, 2024 | 805.60M |
| June 30, 2024 | 583.20M |
| March 31, 2024 | 432.30M |
| December 31, 2023 | -52.70M |
| September 30, 2023 | 504.80M |
| June 30, 2023 | 400.00M |
| March 31, 2023 | 383.70M |
| December 31, 2022 | -262.40M |
| September 30, 2022 | 601.90M |
| June 30, 2022 | 697.70M |
| March 31, 2022 | 103.90M |
| December 31, 2021 | 769.80M |
| September 30, 2021 | 743.40M |
| June 30, 2021 | 1.155B |
| March 31, 2021 | 676.40M |
| December 31, 2020 | -468.10M |
| September 30, 2020 | 1.097B |
| Date | Value |
|---|---|
| June 30, 2020 | 1.844B |
| March 31, 2020 | 1.206B |
| December 31, 2019 | 1.695B |
| September 30, 2019 | 1.605B |
| June 30, 2019 | 1.777B |
| March 31, 2019 | 1.332B |
| December 31, 2018 | 1.670B |
| September 30, 2018 | 1.545B |
| June 30, 2018 | 834.50M |
| March 31, 2018 | 1.252B |
| December 31, 2017 | 1.343B |
| September 30, 2017 | 1.349B |
| June 30, 2017 | 846.40M |
| March 31, 2017 | -830.00M |
| December 31, 2016 | 1.393B |
| September 30, 2016 | 816.30M |
| June 30, 2016 | 859.00M |
| March 31, 2016 | 860.30M |
| December 31, 2015 | 854.28M |
| September 30, 2015 | 666.25M |
| June 30, 2015 | 917.36M |
| March 31, 2015 | 635.21M |
| December 31, 2014 | 825.97M |
| September 30, 2014 | 851.49M |
| June 30, 2014 | 926.59M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AbbVie, Inc. | 7.305B |
| Gilead Sciences, Inc. | 4.798B |
| Amgen, Inc. | 3.654B |
| Regeneron Pharmaceuticals, Inc. | 1.427B |
| Eli Lilly & Co. | 4.157B |